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i.org/1overall survival and occurrence of shocks is important if improved patient selection is
desired. We prospectively studied the predictive value of biomarkers and indexes of cardiac
and renal function and spectral microvolt T-wave alternans testing and 24-hour Holter
variables in a population who underwent ﬁrst ICD implantation. Consecutive patients in
sinus rhythm with ischemic or dilated cardiomyopathy scheduled for primary or secondary
prophylactic ICD implantation were enrolled. Exercise microvolt T-wave alternans and
24-hour Holter for number of ventricular premature contractions (VPCs), deceleration
capacity, heart rate variability, and heart rate turbulence were done. Death of any cause
and ﬁrst appropriate ICD shock were deﬁned as end points. Over 33 – 15 months of follow-
up, 36 of 253 patients (14%) received appropriate shocks and 39 of 253 patients (15%) died.
Only 3 of 253 patients (1%) died after receiving at least 1 appropriate shock. In univariate
analyses, New York Heart Association class, ejection fraction, N-terminal pro brain-type
natriuretic peptide (NT-proBNP), renal function, ICD indication, deceleration capacity,
heart rate variability, and heart rate turbulence were predictive of all-cause mortality and
VPC number and deceleration capacity predicted ﬁrst appropriate shock. NT-proBNP
(‡1,600 pg/ml) was identiﬁed as the only independent predictor of all-cause mortality
(hazard ratio 3.0, conﬁdence interval 1.3 to 7.3, p [ 0.014). In contrast, VPC number
predicted appropriate shocks (hazard ratio 2.3, conﬁdence interval 1.0 to 5.5, p[ 0.047) as
the only independent risk marker. In conclusion, NT-proBNP is a strong independent
predictor of mortality in a typical prospective cohort of newly implanted patients with ICD,
among many electrocardiographic and clinical variables studied. Number of VPCs was
identiﬁed as a predictor of appropriate shocks (clinicaltrials.gov: NCT02010515).  2016
The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-
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2016;118:86e94)Implantable cardioverter deﬁbrillators (ICDs) are recom-
mended for the prevention of sudden cardiac death (SCD).1
However, a large number of patients never receive an appro-
priate shock from their device.2 Therefore, predictors for
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Microvolt T-wave alternans (MTWA) has been shown to
improve the selection of primary prophylactic ICD candi-
dates3 and has been recommended in sudden death risk
stratiﬁcation guidelines.1 Unfortunately, later trials have yiel-
ded equivocal ﬁndings.4e7 Other traditional electrocardio-
graphic risk stratiﬁers, such as Holter variables,8 especially
parameters of autonomic tone,9,10 and the signal-averaged
electrocardiogram (SAECG)11 have never been tested in
patients with ICD, although they have been used as inclusion
criteria in large randomized ICD trials.11,12 We, therefore,
prospectively studied a combination of selected risk stratiﬁers
in a consecutive single-center ICD cohort featuring primary
and secondary prophylactic indications. Only ischemic or
nonischemic dilated cardiomyopathy patients were enrolled,
and stable sinus rhythm was a major inclusion criteria. The
prognostic value for all-cause mortality or ﬁrst appropriate
shock was evaluated for ventricular premature contractions
(VPCs), nonsustained ventricular tachycardia, heart rateccess article
4.0/).
www.ajconline.org
Heart Failure/Noninvasive ICD Shock Prediction 87variability (HRV), heart rate turbulence and acceleration and
deceleration capacity from Holter monitoring, exercise
MTWA (Cambridge heart method) and clinical variables, such
as N-terminal pro brain-type natriuretic peptide (NT-proBNP),
renal function, cardiac disease, and ICD indication.
Methods
Consecutive patients who underwent ﬁrst ICD or cardiac
resynchronization therapy with deﬁbrillator (CRT-D) im-
plantation from 2008 to 2011 at our institution were eligible
for this prospective observational study. All devices were
implanted for approved primary and secondary prophylactic
indications.1 Inclusion criteria were ischemic or dilated
cardiomyopathy, sinus rhythm, and age 18 years. All pa-
tients gave their informed consent to the protocol. The study
was conducted according to the Declaration of Helsinki and
was registered (clinicaltrials.gov: NCT02010515). Patients
not in sinus rhythm at baseline were excluded.
Prospectively, all patients underwent medical history,
physical examination, and standard blood tests including
serum creatinine13 for calculation of the estimated glomer-
ular ﬁltration rate using a constant c of 175 and NT-proBNP,
a 12-lead electrocardiogram (ECG, MacVU 5500; GE,
Milwaukee, Wisconsin), and echocardiography using the
Simpson method for determination of left ventricular ejec-
tion fraction. Additionally, SAECG, exercise-based
MTWA, and 24-hour Holter ECG were performed.
SAECG was recorded using a GE Marquette MAC 5000
(General Electric, Fairﬁeld, Connecticut). In 30 of 253
patients (12%), an SAECG could not be recorded or was not
analyzable for technical reasons.
MTWA testing was performed in 223 of 253 patients
(88%) using a CH2000 station (Cambridge Heart, Tewksbury,
Massachusetts) and heart rate elevation by means of exercise
in 161 of 223 patients (72%).14 In patients unable to undergo
exercise testing and scheduled for implantation of an atrial
lead, testing was done after the ICD/CRT-D implantation by
atrial (43 of 223, 19%) or biventricular pacing (19 of 223,
9%).15 It could not be completed in 30 patients because
patients who underwent single-lead ICD implantation were
unable to undergo ergometry. Beta blockers were not withheld
as recommended.16 The test results were reviewed according
to standard rules and graded by 2 independent and blinded
investigators (in brief: sustained alternans 1.9 mV and
alternans ratio >3 lasting at least 1 minute with an onset heart
rate110 beats/min: positive; maximum heart rate with noise
1.8 mV, rate of premature ventricular complexes <10% and
without sustained alternans 105 beats/min [A-rules] or 80
beats/min with a difference to the maximum heart rate 5
beats/min [B-rules]: negative; otherwise: indeterminate).14
Positive and indeterminate results were grouped as non-
negative results.
Dual-channel 24-hour Holter ECG was recorded using a
digital portable recorder (Lifecard CF; Delmar Reynolds/
Spacelabs Healthcare, Snowqualmie, Washington); 235 of
253 (93%) were accepted for statistical analysis; the
remaining 18 patients had recordings of poor quality or a too
short time period and were excluded from the ﬁnal analysis.
Holter analysis was done using semiautomatic software
(Pathﬁnder, version 8.602; Delmar Reynolds/SpacelabsHealthcare). The number of VPC and the number of ven-
tricular runs 3 beats (nonsustained ventricular tachy-
cardia), each normalized for a recording time of 24 hours,
were determined.8 HRV including standard deviation of RR
intervals (SDNN), root mean square of successive differ-
ences in RR intervals, and frequency domain parameters
(quotient of low frequency and high frequency) were
calculated (HRV-Tools, version 1.74; Delmar Reynold/
Spacelabs Healthcare).17 Heart rate turbulence (HRT)
including turbulence onset and slope9 and acceleration and
deceleration capacity10 were computed by means of open-
source HRT software (Librasch Calc, 1.02 Schneider R
and Schmidt G, TU Munich). Holter recordings with 30%
atrial pacing (n ¼ 20) were excluded from HRV, HRT, and
deceleration capacity analysis for methodological reasons,
HRT could not be determined in patients without suitable
VPC (n ¼ 19). Therefore, HRV, HRT, acceleration, and
deceleration capacity were available in 210 of 235 (89%),
196 of 235 (83%), 209 of 235 (89%), and 210 of 235 (89%),
respectively.
ICD or CRT-D device selection at implantation varied
(Biotronik GmbH, Berlin, Germany; Medtronic Inc., Fridley,
Minnesota; Boston Scientiﬁc, Natick, Massachusetts)
according to patient needs and at the implanter’s discretion.
The ﬁrst programming was standardized: Two zones were
programmed with the VT zone starting at 170 beats/min
lasting 2.5 to 5 seconds or 16 to 24 beats and treated with
antitachycardia pacing (ATP, standard: 2  3 programmed),
followed by maximum output high-voltage shocks if recur-
rent ATP failed to terminate the arrhythmia. The VF zone
started at 220 beats/min lasting for 1 to 2.5 seconds or 12 of
16 to 18 of 24 beats and was treated with maximum output
high-voltage shocks (after ATP during charging if available).
In case of a history of VT or induced sustained VTs, the
average rate of clinical VTs prompted a VT zone at least 10
beats/min slower. Algorithms for improved detection of
supraventricular arrhythmias (onset, stability, Biotronik
“S.M.A.R.T.”, Medtronic “Wavelet” or “PRLogic”, Boston
Scientiﬁc “RhythmID”) were activated. Single-chamber ICDs
were programmed to ventricular demand pacing with 40
beats/min, dual-chamber ICD, and CRT-D to DDD 50 or 60
to 130 beats/min. Dual-chamber ICD had prolonged AV
intervals set to reduce the percentage of RV pacing. Standard
programming could be varied during follow-up according to
individual patient’s needs.
Prospectively deﬁned co-primary end points of the study
were (1) the occurrence of a ﬁrst appropriate ICD shock for
malignant ventricular arrhythmia (as determined from the
ICD’s EGM recordings) and (2) all-cause mortality. As we
aimed to identify predictors of truly life-saving ICD thera-
pies, successful or inappropriate ATP or inappropriate ICD
shocks were not considered as end points. Data from our
institution, other hospitals, the patients’ general practitioner,
and local authorities were reviewed for assessment of all-
cause mortality.
All statistical analyses were performed using SPSS,
version 21.0 (SPSS Inc., Chicago, Illinois) and SPSS
SamplePower, version 3. For the purpose of sample size
calculation, annual mortality was estimated as 9% taking
into account enrollment of more elderly patients with more
co-morbidities. According to the Schoenfeld formula,18 a
88 The American Journal of Cardiology (www.ajconline.org)total of 36 events provides a power of 80% for a 2-sided test
at the usual 5% signiﬁcance level in the Cox proportional
hazards regression as long as the hazard ratio (HR) is larger
than 2.45 comparing with equally sized groups. All results
are presented as mean  SD for continuous variables and as
frequencies (proportions) for categorical variables. Kaplan-
Meier survival probability curves were computed to
compare event rates in subgroups using the log-rank test.
Univariate predictors with a p <0.1 were included in
multivariate Cox proportional hazard models and stepwise
backward elimination was performed. In addition, bio-
markers and electrocardiographic predictors of all-cause
mortality with a univariate p <0.1 were adjusted for clin-
ical predictors with a p <0.1 to avoid that interrelated var-
iables such as Holter parameters of autonomic tone (SDNN,
quotient of low frequency and high frequency, HRT, and
acceleration and deceleration capacity) are introduced to the
Cox model simultaneously. Missing values were excluded
from analysis (complete case analysis). Receiver operating
characteristic (ROC) curves were used to quantitate test
characteristics. Odds ratios (ORs) were calculated using
contingency tables. For all tests, a p <0.05 was accepted for
statistical signiﬁcance.
Results
A total of 253 patients with ischemic or dilated cardio-
myopathy (71% and 29%, respectively) were enrolled at
ﬁrst ICD implantation. ICD therapy was recommended for
primary prophylaxis of SCD in 69% and for secondary
prophylaxis in 31%, respectively; 43% of the latter had been
successfully resuscitated from cardiac arrest due to VF.
Patients were predominantly male (77%), with a mean age
of 67  11 years, mean ejection fraction was 30  11%,
53% of patients presented with New York Heart Association
functional class II symptoms, 44% with class III symptoms,
and 3% with class I symptoms, respectively (of the latter, all
had secondary prophylactic indication). NT-proBNP aver-
aged 3,433  6,023 pg/ml, and estimated glomerular
ﬁltration rate averaged 68.2  24.5 ml/min/1.73 m2. Most
patients received typical heart failure medications (angio-
tensin-converting enzyme inhibitor or angiotensin receptor
blocker 93%, beta-adrenergic receptor blockers 92%, loop
diuretics 61%, and mineralocorticoid receptor antagonist
54%). Only few patients were treated with antiarrhythmic
drugs (amiodarone 18% and ﬂecainide 2%). A history of
paroxysmal atrial ﬁbrillation was known at enrollment in
29% of patients, 81% had arterial hypertension diagnosed,
and 30% had diabetes mellitus, respectively. Patients were
implanted with single-chamber ICDs in 39% and dual-
chamber ICDs in 35%. The remaining 26% were given a
device for cardiac resynchronization therapy (CRT-D).
Mean QRS duration was 125  31 ms; 129 of 253 (51%)
had a QRS duration <120 ms, typical left bundle branch
block was present in 68 of 253 (27%) of the cohort. Mean
QT interval was 418  52 ms. SAECG revealed a mean
ﬁltered QRS duration of 149  29 ms, a mean RMS voltage
of 29  68 mV, and a mean duration of low amplitude
signals of 50  28 ms. The MTWA test result was positive
in 72 of 223 (32%), it was negative in 78 of 223 (35%)
following A-rules and in 118 of 223 (53%) followingB-rules, respectively. Indeterminate test results were found
in 73 of 223 (33%) using A-rules and 33 of 223 (15%) using
B-rules. Indeterminate test results (following B-rules) were
caused by excessive ectopic beats in 15 of 33 (45%) of
indeterminate MTWA patients, by chronotropic incompe-
tence and a maximal heart rate <80 beats/min in 10 of 33
(30%) indeterminate patients, and poor technical quality or
bad signal to noise ratio in 8 of 33 (25%) of all indetermi-
nate tests, respectively. Mean heart rate on Holter moni-
toring was 69  11 beats/min, mean number of VPC
normalized to 24 hours was 2,356  4,351; 38 of 235
patients (16%) had at least 1 ventricular run 3 beats. Mean
SDNN was 90  40 ms, root mean square of successive
differences in RR intervals 23  15 ms, and mean quotient
of low frequency and high frequency 2.9  3.9; mean tur-
bulence onset from HRT was 0.1  1.8%, mean turbu-
lence slope 3.2  4.1 ms/RR interval, mean acceleration
capacity 8.2  8.6 ms, and mean deceleration capacity
0.4  7.3 ms.
Overall follow-up was 33  15 months (range: 10 days,
this patient died due to progressive heart failure early after
ICD implantation, to 61 months). Appropriate ICD shocks
occurred in 36 of 253 patients (14%). In 18 events, shocks
were delivered for malignant ventricular arrhythmia in the
VF zone (at a mean cycle length of 235  22 ms). Another
18 shock events occurred in the VT zone following failed
anti-tachycardia pacing for an index VT with a mean cycle
length of 302  17 ms. Thirty-nine of 253 patients (15%)
died during FU, only 3 of 253 (1%) received an appropriate
ICD shock before death.
Kaplan-Meier analysis showed that VPC frequency on
Holter (median 525 beats/24 hours; p ¼ 0.01; Figure 1) and
deceleration capacity from Holter (median 2.2 ms; p ¼ 0.03;
Figure 1) were associated with a higher probability of ICD
shock.
MTWA did not reach statistical signiﬁcance when
assessing its association with ICD shocks (non-negative vs
negative; p ¼ 0.20). When indeterminate MTWA tests were
omitted from the non-negative group, the comparison still
did not reach statistical signiﬁcance (positive vs negative
following B-rules, p ¼ 0.15; Figure 1). Negative MTWA
(vs non-negative) following B-rules had a sensitivity and a
speciﬁcity of 58% and 55% (negative/positive predictive
value 89%/17%; OR 1.7; 95% conﬁdence interval [CI] 0.8
to 3.6; p ¼ 0.25) to predict ﬁrst appropriate shock.
No statistically signiﬁcant difference for the probability
of ICD shocks was found in male gender (p ¼ 0.23;
Figure 1), secondary prophylactic ICD indication (p ¼ 0.16;
Figure 1), depressed RMS voltage from SAECG (median
19 mV; p ¼ 0.19; Figure 1), occurrence of nonsustained
ventricular tachycardia during Holter monitoring (p ¼ 0.37),
ejection fraction (median 30%, p ¼ 0.77), NT-proBNP
(median 1,599 pg/ml; p ¼ 0.70), estimated glomerular
ﬁltration rate (median 66 ml/kg/1.73 m2; p ¼ 0.29), and
HRT (onset median 0.1%, p¼ 1.00; slope median 1.9 ms/RRi,
p ¼ 0.86), respectively.
Kaplan-Meier analysis revealed a statistically signiﬁcant
association of all-cause mortality and the following variables:
New York Heart Association functional class (I/II vs III; p ¼
0.03), ejection fraction (p ¼ 0.02; Figure 2), NT-proBNP
(p ¼ 0.0002; Figure 2), estimated glomerular ﬁltration rate
Figure 1. Kaplan-Meier estimates of the probability of survival free of appropriate ICD shock: (A) VPC, (B) DC, (C) MTWA results (following
B-rules, indeterminates were omitted for this analysis), (D) gender, (E) ICD indication, and (F) RMS voltage. All variables were dichotomized by median.
DC ¼ deceleration capacity.
Heart Failure/Noninvasive ICD Shock Prediction 89(p ¼ 0.004; Figure 2), ICD indication (p ¼ 0.02; Figure 2),
SDNN (median 84 ms; p ¼ 0.046; Figure 2), quotient of low
frequency and high frequency (median 1.9, p ¼ 0.043;
Figure 2), HRT slope (p ¼ 0.01; Figure 2), and deceleration
capacity (p ¼ 0.03; Figure 2), respectively. A nonsigniﬁcant
trend was found for age (p ¼ 0.07) and VPC (p ¼ 0.08),
respectively. When both HRT variables were grouped using
dichotomization by median, a nonsigniﬁcant trend was found
(onset 0.1% and/or slope 2 ms/RRi vs onset >0.1% and
slope <2 ms/RRi; p ¼ 0.06). No statistically signiﬁcant
differences were found for ischemic cardiomyopathy (p ¼
0.18), MTWA (negative vs non-negative; p ¼ 0.16), gender
(p ¼ 0.34), nonsustained ventricular tachycardia during
Holter monitoring (p ¼ 0.42), and HRT onset (p ¼ 0.37),
respectively. Negative MTWA (vs non-negative) following
B-rules had a sensitivity and a speciﬁcity of 59% and 55%
(negative/positive predictive value 88%/19%; OR 1.7; 95%
CI 0.8 to 3.7; p ¼ 0.19) to predict all-cause mortality. In
addition, univariate Cox regression was performed, and the
results for prediction of ﬁrst appropriate shock and all-cause
mortality are given in Tables 1 and 2 (left columns). ROC
analysis was performed to determine the diagnostic utility of
the variables for the prediction of appropriate ICD shocks and
of all-cause mortality, respectively (Tables 1 and 2, rightcolumns). NT-proBNP showed the largest area under the
curve (p ¼ 0.000003; Figure 3).
Variables with a univariate p <0.10 were entered in
multivariate Cox regression models. VPC frequency was
identiﬁed as the only independent predictor of the occur-
rence of appropriate ICD shocks (HR 2.3; 95% CI 1.0 to
5.5; p ¼ 0.047). For the prediction of all-cause mortality,
univariate variables with p <0.1 were adjusted for age, New
York Heart Association functional class, ejection fraction,
estimated glomerular ﬁltration rate, and ICD: NT-proBNP
remained as a signiﬁcant predictor of all-cause mortality
VPC count and deceleration capacity were associated with
mortality by trend (Table 3). When NT-proBNP was entered
into multivariable models (including just one of the Holter
variables of autonomic tone per model), it remained sig-
niﬁcant in each ﬁnal model after stepwise backward elimi-
nation (data not shown) and was, therefore, proved to be an
independent predictor of all-cause mortality.
Discussion
This study in a contemporary ICD ﬁrst implant popu-
lation of ischemic and dilated cardiomyopathies revealed a
number of mortality predictors in contrast to only few
Figure 2. Kaplan-Meier estimates of the probability of overall survival: (A) LVEF, (B) NT-proBNP, (C) eGFR, (D) ICD indication, (E) SDNN, (F) quotient
of LF/HF, (G) HRT, and (H) DC. All variables were dichotomized by median. DC ¼ deceleration capacity; eGFR ¼ estimated glomerular ﬁltration rate;
LF/HF ¼ low frequency/high frequency; LVEF ¼ left ventricular ejection fraction.
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dictor for mortality—NT-pro-BNP—revealed an excellent
C-statistic, whereas the corresponding parameter for
appropriate shock, VPC rate on Holter, was less accurate.
Thus, in contemporary patients with ICD, a good predic-
tion of mortality risk by a speciﬁc marker does not coincide
with a similarly good prediction of ICD shock risk. This is
in contradiction with a large body of literature collected in
patients without ICDs, where good markers of SCD are
usually also good markers of all-cause mortality. It may
best be explained that the mode of death in patients with
ICD is converted from sudden death to cardiac death.19,20
Risk markers are less investigated in 100% ICD cohorts
and 2 studies are published on MTWA,4,21 but the pre-
dictive value of combined risk markers has not been
simultaneously studied in patients with ICD. We, there-
fore, hypothesized that a combination of known risk
markers in post-MI populations could yield important
insights in contemporary ICD populations.
Altogether, only 14% of our patients (or 5.5% annually)
received appropriate ICD shocks. This is similar to the
rate reported in the Sudden Cardiac Death in Heart Failure
Trial (SCD-HeFT; 5%)22 but less than in the Multicenter
Automatic Deﬁbrillator Implantation Trial-II (MADIT-II;
11%).23 Similarly, the observed all-cause mortality of
6% per year in our study was equal to SCD-HeFT
(6%)22 but less than MADIT-II (9%).23 Extrapolating
patient characteristics of the previous trials and comparing
with our own data from the present study, an overall lower
risk of death and particularly shock events is found. This
may be explained by an increasing number of early
revascularization in patients with acute myocardialinfarction and improved pharmacological therapy over
time. Of note, the ICD programming in our cohort was
restrictive using a moderate detection delay following
expert recommendation at the beginning of the study24 and
a large number of ATP in the VT zone resulting in a low
annual shock rate as desired. As it has been shown that a
large number of shocks is delivered for nonfatal
arrhythmia,25 we decided not to consider ATP as an end
point to increase the likelihood that the ICD treatment is
truly life saving. However, the ICD shocks used as a sur-
rogate will still overestimate the true rate of SCD even in
our cohort; nevertheless, no better estimation of true SCD
rate in patients with ICD is available.
Left ventricular ejection fraction was critical in the
landmark ICD trials regarding primary prevention of
SCD11,12,22 but did not predict arrhythmic events in our
cohort. NT-proBNP known as an accurate marker of heart
failure status and mortality26 was identiﬁed as the best
independent predictor of all-cause mortality in our study. In
contrast to a recently published retrospective analysis,27
NT-proBNP was not a predictor of ICD shocks in our
cohort. In that registry, NT-proBNP was a strong predictor
of ventricular arrhythmia (HR 5.75, p <0.001). ICD pro-
gramming was similar in that registry. However, ATP,
contributing 42% of end points in that registry, was not
considered as an end point in our study. In addition, that
registry did not include consecutive patients but those with
incidental available NT-proBNP taken for other reason, for
example, worsening of heart failure within 9 months of the
date of ICD implantation, which may have led to a selection
bias. Similar to NT-proBNP results, our patients with pri-
mary prevention ICD indication were at higher risk of
Table 1
Univariate hazard ratio (95% conﬁdence interval) and area under the curve from receiver operating characteristics analysis for the prediction of appropriate ICD
shocks. Cox regression was performed with dichotomized variables by the median, receiver operating characteristics analysis was done with continuous
variables
Variable APPROPRIATE SHOCK
N Univariate ROC
HR (95% CI) P AUC (95% CI) P
Men 253 (100%) 1.8 (0.7-4.6) 0.24
Age ( 70 years 253 (100%) 1.0 (0.5-1.9) 0.99 0.48 (0.4-0.57) 0.76
NYHA functional class III 253 (100%) 1.4 (0.7-2.8) 0.38
left-ventricular ejection fraction ( 30%) 253 (100%) 0.9 (0.5-1.8) 0.77 0.49 (0.38-0.59) 0.79
NT-proBNP ( 1600 pg/mL) 223 (88%) 1.2 (0.6-2.4) 0.70 0.47 (0.35-0.59) 0.61
glomerular ﬁltration rate
( 65 mL/min/1.73m2)
253 (100%) 0.7 (0.4-1.4) 0.29 0.42 (0.32-0.52) 0.12
ICD indication (secondary prophyl.) 253 (100%) 1.6 (0.8-3.1) 0.17
Ischemic cardiomyopathy 253 (100%) 1.1 (0.5-2.3) 0.79
ECG and SAECG
QRS ( 120 ms) 253 (100%) 0.8 (0.4-1.5) 0.44 0.46 (0.35-0.56) 0.40
ﬁltered QRS duration (> 145 ms) 223 (88%) 0.9 (0.4-1.9) 0.84 0.52 (0.41-0.64) 0.70
RMS voltage (< 20 mV) 223 (88%) 1.7 (0.8-3.6) 0.20 0.61 (0.49-0.74) 0.05
Low-amplitude signals ( 45 ms) 223 (88%) 1.2 (0.6-2.6) 0.58 0.55 (0.44-0.67) 0.36
T wave alternans
MTWA: non-negative vs. negative* 223 (88%) 1.6 (0.8-3.2) 0.20
MTWA: positive vs. negative 190 (75%) 1.7 (0.8-3.7) 0.16
Holter
VPC (> 525 beats/24h) 235 (93%) 2.4 (1.2-5.0) 0.02 0.6 (0.48-0.71) 0.07
Deceleration capacity (< 2.2 ms) 210 (83%) 2.4 (1.1-5.1) 0.03 0.6 (0.49-0.71) 0.08
Acceleration capacity (< e6.0 ms) 209 (83%) 2.5 (1.1-5.8) 0.03 0.68 (0.58-0.77) 0.003
HRV: SDNN (< 85 ms) 210 (83%) 0.6 (0.3-1.4) 0.25 0.41 (0.31-0.51) 0.11
HRV: low frequency/high frequency (< 1.9) 202 (80%) 1.2 (0.5-2.5) 0.67 0.47 (0.35-0.58) 0.61
HRT: turbulence onset (> 0.1%) 196 (77%) 1.0 (0.5-2.1) 1.00 0.46 (0.34-0.59) 0.53
HRT: turbulence slope (2.0 ms/RRi) 196 (77%) 0.9 (0.4-2.0) 0.86 0.48 (0.37-0.58) 0.68
AUC ¼ area under the curve; CI ¼ conﬁdence interval; ECG ¼ electrocardiogram; HR ¼ Hazard ratio; HRT ¼ Heart rate turbulence; HRV ¼ Heart rate
variability; ICD ¼ implantable cardioverter deﬁbrillator; MTWA ¼ microvolt T-wave alternans; NT-proBNP ¼ N-terminal pro brain-type natriuretic peptide;
NYHA¼ New York Heart Association; ROC ¼ Receiver operating characteristics; SAECG¼ signal-averaged electrocardiogram; SDNN ¼ standard deviation
of RR intervals; VPC ¼ ventricular premature complexes.
Bold values are statistically signiﬁcant (p <0.05).
* B rules; using A rules, HR was 1.4 (95% CI, 0.7 to 3.1; p ¼ 0.38).
Heart Failure/Noninvasive ICD Shock Prediction 91mortality, but not less ICD shock risk, which also may be
explained by our restrictive shock end point.
The best electrocardiographic markers of ICD shocks and
all-cause mortality on univariate analysis in this study are
VPC count on Holter and deceleration capacity. MTWA
failed to be a signiﬁcant predictor of ICD shocks or all-cause
mortality in this prospective study of typical patients with
ICD. We cannot rule out that an HR of 1.6 to 1.7 for the
prediction of appropriate ICD shocks may have led to a
signiﬁcant result if a larger cohort had been studied. How-
ever, the HR of MTWA is lower than that of comparative
other markers. Ventricular ectopy has been identiﬁed as a
risk stratiﬁer in patients with post-myocardial infarction
decades ago and multiple studies found nonsustained ven-
tricular tachycardia as a useful risk marker of SCD.8 To
date, the role of VPCs and nonsustained ventricular tachy-
cardia has not been systematically investigated in patients
with ICD. The predictive value of VPC count (HR 2.3) was
better than that of nonsustained ventricular tachycardia (HR
1.5). However, its discriminative power was not as good as
for all-cause mortality. HRT is known as a powerful risk
stratiﬁcation marker for cardiac mortality and arrhythmicevents.9 In line with the ﬁndings of previous HRT trials,9,28
turbulence slope had a good predictive value for all-cause
mortality in the present study. Impaired heart rate deceler-
ation capacity was a strong predictor for all-cause mortality
in a multicenter cohort of patients early after myocardial
infarction and without ICD implantation10; in the presence
of a very strong mortality predictor, such as NT-proBNP,
deceleration capacity was not an independent mortality
marker in our cohort.
MTWA trials yielded contradictory results in previous
studies investigating patients with ischemic cardiomyopathy: a
non-negative MTWA test was associated with a signiﬁcantly
increased risk for arrhythmic mortality or arrhythmic
events29,30 and a high negative predictive value has been re-
ported.21 In contrast, MTWA test result did not predict
arrhythmic events or mortality in a prospective substudy of the
SCD-HeFT trial among others.4,6,28 In our study, nonsigniﬁ-
cant higher event rates were observed in non-negativeMTWA.
In addition, the amount of positiveMTWA test results is lower
in our cohort, which might have impact on its predictive value.
Of note, our study extended to patients with ICD with non-
ischemic cardiomyopathy (29%), which may explain
Table 2
Univariate hazard ratio (95% conﬁdence interval) and area under the curve from receiver operating characteristics analysis for the prediction of all-cause
mortality. Cox regression was performed with dichotomized variables by the median, receiver operating characteristics analysis was done with continuous
variables
Variable ALL-CAUSE MORTALITY
N Univariate ROC
HR (95% CI) P AUC (95% CI) P
Men 253 (100%) 0.7 (0.4-1.4) 0.35
Age ( 70 years 253 (100%) 1.8 (0.9-3.4) 0.08 0.59 (0.5-0.68) 0.08
NYHA functional class III 253 (100%) 2.3 (1.1-5.0) 0.04
left-ventricular ejection fraction ( 30%) 253 (100%) 2.6 (1.1-5.9) 0.02 0.66 (0.58-0.75) 0.001
NT-proBNP ( 1600 pg/mL) 223 (88%) 4.3 (1.8-9.9) <0.001 0.76 (0.67-0.84) <0.001
glomerular ﬁltration rate ( 65 mL/min/1.73m2) 253 (100%) 2.6 (1.3-5.0) 0.01 0.66 (0.57-0.75) 0.001
ICD indication (primary prophyl.) 253 (100%) 3.0 (1.2-7.8) 0.02
Ischemic cardiomyopathy 253 (100%) 1.7 (0.8-3.7) 0.19
ECG and SAECG
QRS ( 120 ms) 253 (100%) 0.9 (0.5-1.8) 0.87 0.51 (0.41-0.61) 0.84
ﬁltered QRS duration (> 145 ms) 223 (88%) 1.2 (0.6-2.4) 0.65 0.51 (0.39-0.62) 0.91
RMS voltage (< 20 mV) 223 (88%) 1.0 (0.5-2.0) 0.99 0.47 (0.37-0.58) 0.62
Low-amplitude signals ( 45 ms) 223 (88%) 1.0 (0.5-2.1) 0.93 0.47 (0.37-0.57) 0.62
T wave alternans
MTWA: non-negative vs. negative* 223 (88%) 1.6 (0.8-3.2) 0.16
MTWA: positive vs. negative 190 (75%) 1.6 (0.8-3.4) 0.21
Holter
VPC (> 525 beats/24h) 235 (93%) 1.8 (0.9-3.4) 0.08 0.58 (0.49-0.67) 0.11
Deceleration capacity (< 2.2 ms) 210 (83%) 2.2 (1.1-4.4) 0.03 0.61 (0.52-0.7) 0.04
Acceleration capacity (< e6 ms) 209 (83%) 1.3 (0.7-2.5) 0.45 0.51 (0.41-0.61) 0.92
HRV: SDNN (< 85 ms) 210 (83%) 2.0 (1.0-4.2) 0.05 0.58 (0.48-0.67) 0.16
HRV: low frequency/high frequency (< 1.9) 202 (80%) 2.1 (1.0-4.4) 0.05 0.57 (0.46-0.68) 0.24
HRT: turbulence onset (> 0.1%) 196 (77%) 1.4 (0.7-2.8) 0.37 0.57 (0.48-0.67) 0.21
HRT: turbulence slope (2.0 ms/RRi) 196 (77%) 2.5 (1.2-5.3) 0.02 0.68 (0.58-0.78) 0.001
AUC ¼ area under the curve; CI ¼ conﬁdence interval; ECG ¼ electrocardiogram; HR ¼ hazard ratio; HRT ¼ heart rate turbulence; HRV ¼ heart rate
variability; ICD ¼ implantable cardioverter deﬁbrillator; MTWA ¼ microvolt T-wave alternans; NT-proBNP ¼ N-terminal pro brain-type natriuretic peptide;
NYHA ¼ New York Heart Association; ROC ¼ receiver operating characteristics; SAECG ¼ signal-averaged electrocardiogram; SDNN ¼ standard deviation
of RR intervals; VPC ¼ ventricular premature complexes.
Bold values are statistically signiﬁcant (p <0.05).
* B rules; using A rules, HR was 1.6 (0.8-3.4; p ¼ 0.22).
Figure 3. ROC of NT-proBNP for the prediction of all-cause mortality.
Table 3
Predictors of all-cause mortality adjusted for age, New York Heart
Association functional class, left ventricular ejection fraction, estimated
glomerular ﬁltration rate, and ICD indication
ALL-CAUSE MORTALITY
Adjusted HR (95%CI) P
NT-proBNP  1600 pg/mL 3.0 (1.3-7.3) 0.014
PVC > 525 beats/24h 1.8 (0.9-3.4) 0.082
Deceleration capacity < 2.2 ms 1.9 (0.9-3.8) 0.087
HRV: SDNN < 85 ms 1.7 (0.8-3.6) 0.171
HRV: low frequency/high
frequency < 1.9
1.7 (0.8-3.5) 0.172
HRT: turbulence slope
<2.0 ms/RRi
1.7 (0.7-3.9) 0.216
CI ¼ conﬁdence interval; HR ¼ hazard ratio; HRT ¼ heart rate turbu-
lence; HRV ¼ Heart rate variability; ICD ¼ implantable cardioverter
deﬁbrillator; NT-proBNP ¼ N-terminal pro brain-type natriuretic peptide;
NYHA ¼ New York Heart Association; PVC ¼ premature ventricular
complexes; SDNN ¼ standard deviation of RR intervals.
Bold values are statistically signiﬁcant (p <0.05).
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Heart Failure/Noninvasive ICD Shock Prediction 93differences in the results. However, our ﬁndings pertain
exclusively to the spectral method ofMTWA testing; results of
MTWA measurements on ambulatory ECGs5 might differ
and, therefore, should be explored in the future.
In accordance with previous studies,30 SAECG failed to
predict end points in our cohort which may be best
explained with the high rate of revascularization in current
patients with ICD with CAD or ICM.Disclosures
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